Ocular phenotypes associated with biallelic mutations in BEST1 in Italian patients

Andrea Sodi,1 Francesca Menchini,2 Maria Pia Manitto,3 Ilaria Passerini,4 Vittoria Murro,1 Francesca Torricelli,4 Ugo Menchini1

1Department of Specialized Surgical Sciences, Eye Clinic, University of Florence, Italy; 2Department of Ophthalmology, University of Udine, Italy; 3Department of Ophthalmology, S.Raffaele Hospital, University of Milan, Italy; 4Department of Genetic Diagnosis, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Purpose: To report on the phenotype and the genotype of Italian patients carrying BEST1 mutations on both alleles.

Methods: Five Italian patients from four independent pedigrees with retinal dystrophy associated with biallelic BEST1 variants were recruited from different parts of Italy. Molecular genetic analysis of the BEST1 gene was performed with direct sequencing techniques. All the subjects included in the study were clinically evaluated with a standard ophthalmologic examination, fundus photography, optical coherence tomography scan, and electrophysiological investigations.

Results: Six BEST1 variants were identified. Three, c.1699del (p.Glu557AsnfsX52), c.625delAAC (p.Asn179del), and c.139C>T (p.Arg47Cys), were novel, and three had already been reported in the literature, c.301C>A(p.Pro101Thr), c.934G>A (p.Asp312Asn), and c.638A>G (p.Glu213Gly). Four were missense mutations, and two were deletions. Only one BEST1 mutation was located within one of the four mutational clusters described in typical autosomal dominant Best vitelliform macular dystrophy (BVMD). Four patients showed a BVMD phenotype while one patient presented a clinical picture consistent with autosomal recessive bestrophinopathy (ARB).

Conclusions: Biallelic BEST1 sequence variants can be associated with at least two different phenotypes: BVMD and ARB. The phenotypic result of the molecular changes probably depends on the characteristics and the combination of the different BEST1 mutations, but unknown modifying factors such as other genes or the environment may also play a role.

The human BEST1 gene (OMIM 607854; previously known as VMD2) is located on the long arm of chromosome 11q12 and consists of 11 exons [1,2]. This gene is expressed predominantly in the retinal pigment epithelium (RPE) and encodes a 585-amino acid transmembrane protein, bestrophin-1, which localizes to the basolateral membrane of RPE cells [3]. The BEST1 gene probably functions as a chloride channel but has also been considered an inhibitor of intracellular voltage-dependent Ca2+ channels [4,5].

Mutations in the BEST1 gene have been reported in association with different ocular phenotypes [6]. The first disease shown to be caused by BEST1 sequence variants was Best vitelliform macular dystrophy (BVMD) [2], a retinal disease characterized by a bilateral yellowish yolk-like lesion in the macula [7-9]. BEST1 mutations may also be associated with several other eye diseases, including adult-onset vitelliform macular dystrophy (AOVMD) [10], autosomal dominant vitreo-retinocochoroidopathy (ADVIRC) [11], retinitis pigmentosa [12], and microcornea, retinal dystrophy, cataract, and posterior staphyloma (MRC5) syndrome [13].

Usually the disorders associated with BEST1 mutations are inherited as dominant traits. Thus, in typical pedigrees the affected patients carry a BEST1 mutation on one allele, and BEST1 mutations on both alleles are uncommon. Nevertheless, isolated patients with a biallelic mutation in BEST1 and an apparent BVMD phenotype have occasionally been reported in previous studies on various ethnic groups [10,14-17]. A distinct retinal disorder, named autosomal recessive bestrophinopathy (ARB), has recently been described in association with biallelic BEST1 mutations [18,19]. ARB is characterized by RPE dystrophy throughout the posterior pole, associated with retinal edema. A BEST1 homozygous change was reported in four patients of the same family of Pakistani origin; their phenotype was interpreted as retinitis pigmentosa even though it showed some clinical similarities with the ARB phenotype [12]. Recently limited series of patients with different phenotypes and carrying biallelic BEST1 sequence variants have been reported [20-22]. Therefore, the ocular phenotype of patients carrying a BEST1 mutation on both alleles is still undefined. In the present paper, we report on the phenotype and the genotype

Correspondence to: Vittoria Murro, Department of Specialized Surgical Sciences Eye Clinic, University of Florence, Viale Morgagni 85, 50134 Florence, Italy; Phone: +39-055-411765; FAX: +39-055-4377749; email: vittoria.murro@unifi.it
of five Italian patients from four different pedigrees who carry \textit{BEST1} mutations on both alleles.

**METHODS**

\textit{Clinical evaluation:} We first evaluated the medical records of all the patients whose blood samples were sent to the Laboratory of the Department of Genetic Diagnosis, Azienda Ospedaliera Careggi, Florence, Italy, for molecular genetic analysis of the \textit{BEST1} gene. Patients harboring two \textit{BEST1} mutations (one for each allele) were invited, together with their close relatives, for a detailed clinical examination and for a careful evaluation of their personal and family history.

Five patients from four independent pedigrees were included in the study (Figure 1). Two were enrolled through the Hereditary Retinal Degenerations Referring Center of the Eye Clinic, University of Florence; one was regularly followed at the Eye Clinic of the University of Udine, and two patients were recruited through the Genetic Eye Disease Clinic of the Ospedale S. Raffaele, University of Milan, Italy. Interestingly, the families of both patients from the Florence unit originated from northeastern Italy.

The study adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committees. Moreover, each patient gave written informed consent for his or her involvement.

All the subjects included in the study were clinically evaluated with a standard ophthalmologic examination, fundus photography (Zeiss Retinograph Carl Zeiss, Dublin, CA, in Florence; TRC 50 IX camera and acquisition software Imagenet 2000, Topcon Optical Co., Tokyo, Japan, in Udine and Milan), optical coherence tomography (OCT) scan (Topcon 3D OCT-1000, Topcon Medical Systems Inc., Oakland, NJ, in Florence, Stratus Tomographer, model 3000; Carl Zeiss Meditec, Inc., Humphrey Division, Dublin, CA, in Udine, and Spectral OCT SLO OPKO/OTI, Miami, FL, in Milan), electroculogram (EOG), and electroretinogram (ERG). Electrophysiological investigations (Retimax, Roland Consult, Brandenburg, Germany, in Florence; Veris System, EDI, Inc., San Mateo, CA, in Udine; EREV 2000 LACE Elettronica, Pisa, Italy in Milan) were performed according to the existing ISCEV Guidelines [23,24]. Because of the young age of some of the patients, fluorescein angiography and

---

**Figure 1.** Pedigrees of the four families included in the study, with segregation of mutations. All affected patients carry biallelic \textit{BEST1} mutations.
fundus autofluorescence were performed only in selected cases.

DNA extraction and PCR amplification: After informed consent and a complete family history were received, 10 ml of peripheral blood were obtained from the antecubital vein using EDTA-containing vials. DNA was extracted from 200 μl peripheral using an automated method involving the BioRobot EZ1 workstation (QIAGEN GmbH, Germany).

PCR amplification of 11 exons and flanking intronic regions of the BEST1 gene was performed using 50–100 ng of genomic DNA. Amplification was performed in 50 mmol/1 KCl, 10 mmol/l Tris-HCl, pH 8.3, 5 mmol/l MgCl2, 200 μmol/l dNTPs, and 0.5 μmol/l; for each primer set, AmpliTaq DNA polymerase (1 Unit of AmpliTaq Gold; Applied Biosystems, Foster City, KA) was added for each 25 μl reaction. PCR was performed with a multiblock MWG PCR System; cycling parameters for the reactions were optimized for each exon: 95 °C for 13 min and then 30 cycles of 95 °C for 1 min; “x” °C for 1 min; 72 °C for 51 min (for which x °C is the primers’ annealing temperature) with a final extension of 72 °C for 10 min. The primers used are shown in Table 1. PCR amplification was performed using the Core System-Robotic Station (Beckman Coulter). PCR products were purified with a Biomek NX station (Beckman Coulter). Mutational analysis: Standard cycle-sequencing reactions with BigDye Terminator Mix v1.1 (Applied Biosystems) contained 3–10 ng of purified PCR products in 20 μl and were performed with forward and reverse primers for the initial amplification. The sequencing reactions were precipitated, dried, and then sequenced on a sequencer 3730 DNA Analyzer. Finally, data obtained from the Sequence Analysis Software (Applied Biosystems) were aligned with the wild-type BEST1 gene sequence (GenBank Database). According to the EMQN Best Practice Guidelines, a sequence mismatch was considered a disease-causing mutation only if absent in 300 healthy controls, associated with amino acid change, and confirmed with a new independent PCR.

Alamut 1.5 software (Interactive Biosoftware, Rouen, France) was used to interpret the unclassified variants.

RESULTS

Family A: A 6-year-old child (patient A-3) with a history of macular dystrophy and reduced vision was referred to the Eye Clinic of the University of Florence in May 2006. On examination, the best corrected visual acuity (BCVA) was 20/32 right eye (OD) and 20/50 left eye (OS). Fundus examinations revealed a vitelliform disc in the vitelliform stage in the macular area in both eyes (OU). In OS, two extrafoveal additional vitelliform discs were detected in the temporal area at the posterior pole. EOG showed an Arden ratio of 1.00 OD and 1.12 OS. The photopic electroretinographic (ERG) response was within normal limits while scotopic ERG showed a reduced amplitude (about 25% compared with the average values of the control group). In January 2008, the young patient developed choroidal neovascularization (CNV) with macular hemorrhage in OS and received two photodynamic therapy (PDT) treatments.

At the last examination in July 2010, BCVA was 20/50 OD and 20/100 OS. In OD, fluorescein angiography showed a round hypofluorescent area due to the vitelliform disc, with irregular areas of hyperfluorescence related to localized RPE atrophy, without dye leakage; in OS, hyperfluorescent abnormalities were detected in the macular area, in association with staining of the fibrotic areas, without any sign of dye leakage (Figure 2). OCT scans passing through the macula showed in OU an optically empty lesion with clumping of hyperreflective material on the posterior retinal surface and some irregular thickening of the RPE layer (Figure 2). The patient’s father (patient A-1, age 43 years), mother (patient A-2, age 43 years), and younger brother (patient A-4, age 10 years) showed normal visual acuity, normal fundus appearance, and normal ERG. The EOG response was normal for the proband’s parents (the Arden ratio was 2.40 OD and 3.61 OS for the father, and 1.88 OD and 2.31 OS for the mother).

| Exon | Sense primer (5'-3') | Antisense primer (5'-3') | Annealing temperature (°C) |
|------|----------------------|--------------------------|---------------------------|
| 1    | ACCCAACACCTCCAAGAA   | AGTCCACCTGGGACACCTT      | 60                        |
| 2    | CTTCAAAACCCCAATCG    | CCAAGCACTCCTCCCG        | 60                        |
| 3    | AGTCTCAAGCTCACTCCGC  | TGGGCTGTGAGGCTGGT       | 60                        |
| 4    | AGGAAGCTGGAGGGACCGGA | TTTACCATCATTCCATGTCCT   | 58                        |
| 5    | GCCATCCCTTCTGAGGTTT  | ATCGGATGCTGAGCCGG        | 62                        |
| 6    | GGGGAGGTTGTTGTTGCA   | CGACCGTCTACAGCCTAG       | 60                        |
| 7    | TGATTTCCAGGTTCCACCTAG| CATCTGCTGACTGAGCAG       | 65                        |
| 8    | AGGTTTACAGGCCTCACCTG | CACCTTGAGGAGGACATG       | 60                        |
| 9    | CTTCAAGTCACTAGAGACATA| CTAAGCAGACCCCTGCACTAG    | 65                        |
| 40817| ACTGCTCAGCCCTGGCATC  | GTGAGGCACTGTAGTACGCTG    | 60                        |
| 40818| CTTCAAGTCTGCCTTACTGCT| TGACGAGGCTTGGTAGGCAG     | 60                        |
| 11   | GGTACCTCTCCATGCTTATGCTG | AGCTCTGGGATGACATCGA      | 60                        |

For each exon the forward primer, the reverse primer, and the annealing temperature are indicated.
mother), while the brother showed a reduced Arden ratio (1.23 OD and 1.11 OS).

In the proband, molecular analysis detected two sequence variants of the \textit{BEST1} gene in the heterozygous state: c.
934G>A (p.Asp312Asn) already described in the literature in association with BVMD and the novel variant c.1699del (p.Glu557AsnfsX52) [10]. Both mutations were absent in 300 healthy controls of Italian origin. The second variant is a single base pair deletion and gives rise to a premature stop after 52 nucleotides; therefore, a pathogenic effect is likely. The variant could not be evaluated with the Alamut software, which provides a predictive evaluation only for missense mutations. The patient’s father carried the mutation c.1699del (p.Glu557AsnfsX52) in the heterozygous state and the mother and the brother the mutation c.934G>A (p.Asp312Asn) in the heterozygous state. The pedigree of the family and the segregation of the mutations are shown in Figure 1.

**Family B:** In 2006 patient B-3 was referred to the Eye Clinic of the University of Udine at the age of 6 because she complained of mild visual impairment. BCVA was 20/20 OD and 20/25 OS. Fundus appearance was normal in OD while OS showed a vitelliform disc at the posterior pole (Figure 3). EOG was abnormal in OU, with an Arden ratio of 1.07 OD and 0.89 OS. The amplitude of the ERG response was slightly reduced for all the components (about 30% compared with the average values of the control group). OCT scans showed a normal macular profile in OD and an accumulation of hyperreflective material between the RPE and the neuroretina in OS (Figure 3). The clinical picture remained stable until the last examination in May 2010.

The patient’s father (B-1, age 38 years) and mother (B-2, age 37 years) had normal visual acuity and normal fundus appearance, and their ERG and EOG responses were within normal limits (1.75 OD and 1.80 OS for the father and 1.78 OU for the mother). Molecular analysis detected in this patient a novel BEST1 gene sequence variant, c.625delAAC (p.Asn179del), in the homozygous state. This mutation consists of an in-frame deletion of three base pairs and does not give rise to a premature stop. The mutation was absent in 300 healthy controls of Italian origin. The same mutation was detected in both parents in the heterozygous state (Figure 1). The mutation could not be processed by the Alamut software.
because its scoring systems do not provide a predictive evaluation for deletions.

**Family C:** The proband (patient C-3) was referred to the Eye Clinic of the University of Milan in 2004 at age 15 with a history of reduced vision in both eyes. At examination, BCVA was 20/40 OU. Fundoscopy showed at the posterior pole a vitelliform disc in the vitelliruptive stage with contiguous RPE dystrophy below the macula in OU (Figure 4). An OCT scan showed a bilateral macular optically empty zone containing partially reabsorbed hyperreflective material (Figure 4). ERG was within normal limits while EOG was abnormal with an Arden test of 1.20 OD and 1.54 OS. The clinical picture remained unchanged at the following ophthalmologic examinations in 2008 and 2010. The patient was the product of a consanguineous marriage. The parents underwent an ophthalmological examination in 2008, when the father (C-1) was 50 years old and the mother (C-2) was 47 years old; they had normal visual acuity and normal fundus appearance but were not available for electrophysiological testing. Molecular analysis detected in this patient a novel BEST1 gene sequence variant, c.139C>T (p.Arg47Cys), in the homozygous state. The same mutation was detected in both parents in the heterozygous state and in her elder brother in the homozygous state (Figure 1).

**Family D:** In January 2010, a 16-year-old girl (patient D-3) from northern Italy was referred to the Eye Clinic of the University of Florence with a history of reduced vision in both eyes that started when she was about 6 years old. At examination, her BCVA was 20/25 OD and 20/50 OS. Fundoscopy showed an diffused RPE dystrophy with yellowish deposits at the posterior pole and macular edema (Figure 6). The medical records of the patient demonstrated that no vitelliform disc had ever been detected during the course of the disease. An OCT scan showed bilateral macular...
cystoid spaces (Figure 6). Scotopic ERG was abnormal (amplitude was reduced by about 50% of the average value of the control group) while photopic ERG amplitude was slightly reduced (about 25% of the average values of the controls). The EOG Arden test values were 1.20 OD and 1.50 OS. Fluorescein angiography showed macular hyperfluorescence and small hyperfluorescent spots at mid-periphery, with a higher concentration around the optic disc (Figure 6). In 2008, the patient had received PDT for suspected CNV in OD.

The patient’s father (D-1, age 48 years) and mother (D-2, age 47 years) showed normal visual acuity, normal fundus appearance, and ERG response within normal limits. The mother’s EOG response was normal (the Arden ratios were 1.83 OD and 1.72 OS) while the father presented an Arden ratio of 1.35 OU. The patient’s younger brother (D-4) was examined in another hospital in 2004 when he was 5 years old; at that time, visual acuity and fundus appearance were normal. He was not available for further investigations.

In the proband, molecular analysis detected two sequence variants of the BEST1 gene in the heterozygous state: c.301C>A (p.Pro101Thr) and c.638A>G (p.Glu213Gly); both have already been described in the literature in association with BVMD [25,26]. They were absent in 300 healthy controls of Italian origin. The patient’s father carried the mutation c.301C>A (p.Pro101Thr) in the heterozygous state and the mother the mutation c.638A>G (p.Glu213Gly) in the heterozygous state (Figure 1).

Figure 5. Fundus photographs and optical coherence tomography (OCT) scans of patient C-4. A, B: Bilateral vitelliform discs in the vitelliruptive stage. C, D: Bilateral hyperreflective dome-shaped lesions located between the RPE and the neuroretina. OD represents the right eye; OS represents the left eye.

**DISCUSSION**

BEST1 mutations are usually associated with dominant retinal disorders, and therefore homozygous or compound heterozygous mutations are rare [6]. We report on a series of Italian patients carrying mutations of the BEST1 gene on both alleles.

Two of our patients were compound heterozygotes while three patients (two from the same family) were homozygotes. A significant clinical difference between the compound heterozygous and homozygous patients could not be detected in our series; compound heterozygous mutations were associated with a case of unilateral BVMD and with an ARB phenotype.

We identified six BEST1 variants. Three were novel, and three have already been reported in the literature in association with BVMD, c.301C>A (p.Pro101Thr) [25] and c.638A>G (p.Glu213Gly) [26], or AOVMD, c.934G>A (p.Asp312Asn) [10]. Four were missense mutations, and two were deletions. Only one mutation, c.301C>A (p.Pro101Thr), was located within one of the four mutational clusters described in typical autosomal dominant BVMD [6]. Two of the detected mutations, c.934G>A (p.Asp312Asn) and c.139C>T (p.Arg47Cys), have already been reported in patients carrying another BEST1 mutation on the other allele [18,22]. Interestingly, the patient with c.934G>A (p.Asp312Asn) showed an ARB phenotype [18] while the c.139C>T (p.Arg47Cys) mutation (in the homozygous state) was
associated with bilateral vertical elliptic vitelliform lesions at the posterior pole, a clinical picture more similar to classical BVMD [22]. Moreover, in our series two of the six mutations are located between aminoacids Arg 141 and Lys 289 of the
bestrophin protein where a higher frequency of BEST1 biallelic mutations have recently been reported [22].

The relatively high rate of novel mutations, the report of frequent deletions (rarely associated with the BVMD phenotype), the predominant location outside the BVMD mutational clusters, and the recurrence of some variants in the recessive form of the disease may suggest that certain mutations have a higher predisposition to be pathogenic when present on both alleles.

In our series, the biallelic BEST1 mutations are associated with two different phenotypes, BVMD and ARB. This agrees with recent reports of the association of homozygous or compound heterozygous BEST1 variants with different clinical pictures, ranging from the classical form of BVMD [20,22] to ARB [18,19,22], including some atypical phenotypes [21,22].

The clinical picture of patients A-3, B-3, C-3, and C-4 was consistent with BVMD, although with mild phenotypic differences. The patients had abnormal EOG while ERG was slightly abnormal in patients A-3 and B-3 and normal in the remaining patients. The relatives of patients A-3, B-3, C-3, and C-4 presented normal visual acuity, normal fundus appearance, and ERG response within normal limits. EOG was within normal limits for the parents of the patients A-3 and B-3 but showed a reduced Arden ratio for patient A-4, the younger brother of the proband A-3.

Isolated cases of patients with biallelic BEST1 mutations and a BVMD phenotype have already been reported in literature [10,14-17].

In most of the cases, clinical and histopathological abnormalities were comparable to those found in heterozygous patients [15]. Similarly, our BVMD patients did not show a significantly more severe picture than that usually described in BVMD patients carrying a single BEST1 mutation; nevertheless, mild ERG abnormalities were found in patients A-3 and B-3. The clinical expressivity was variable as the BEST1 biallelic variants were associated with typical but also multifocal or unilateral BVMD phenotypes.

The heterozygous relatives of our BVMD patients did not have fundus or ERG abnormalities and showed normal EOG responses in most of the cases. Clinical data on heterozygous relatives of patients carrying BEST1 biallelic mutations have not been reported in detail in the literature; we can only speculate from the available data that some heterozygous relatives may be clinically affected while others may show a normal fundus appearance [10,15-17]. In a recent paper, the heterozygous relatives of a patient with a homozygous BEST1 mutation associated with a classical BVMD phenotype showed neither fundus nor EOG abnormalities [20].

The phenotype of patient D-3 was significantly different from those of the other patients, and it is consistent with the clinical diagnosis of autosomal recessive bestrophinopathy (ARB) [18,19].

This patient carried two BEST1 mutations already described in the literature in association with BVMD. BEST1 variants detected in association with the ARB phenotype have already been reported in BVMD [10,14] and in AOVMD [22]. These data are consistent with the hypothesis that in patients carrying biallelic BEST1 mutations the resulting phenotype is determined by the interaction of the pathogenic effects of the different mutations on both alleles.

The abnormal EOG response of the patient’s father is not in agreement with previous reports where all the heterozygous carriers showed a normal EOG [18]. EOG abnormalities reported in isolated heterozygous cases of clinically healthy relatives of patients carrying biallelic BEST1 mutations may be related to the influence of unknown genetic or environmental factors, even if technical problems or poor collaboration from the patient cannot be excluded.

Previous findings and our observations show that sequence variants of the BEST1 gene on both alleles can be associated with at least two different phenotypes, BVMD and ARB. The phenotypic result of the molecular changes probably depends on the characteristics and the combination of the different BEST1 sequence variants, but unknown modifying factors such as other genes or the environment may also play a role.

Because of this phenotypic heterogeneity, BEST1 mutations may be involved in retinal diseases other than those already identified. A clearer understanding of the BEST1 mutations spectrum and its associated phenotypes is warranted for better clinical evaluation, genetic counseling, and patient selection for possible future treatments.

ACKNOWLEDGMENTS

The Authors report no proprietary interest or financial support. The authors thank Dr Luisa Pierro (S. Raffaele Hospital, Milan, Italy) and Dr Ugo Introini (S. Raffaele Hospital, Milan, Italy) who kindly provided OCT images and fundus photographs of family C.

REFERENCES

1. Marquardt A, Stohr A, Passmore LA, Kramer F, Rivera A, Weber BH. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best’s Disease). Hum Mol Genet 1998; 7:1517-25. [PMID: 9700209]
2. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren G, Andreasson S, Vujic M, Bergen AA, McGarty-Dugan V, Figueroa D, Austin CP, Metzker ML, Caskey CT, Wadellus C. Identification of the gene responsible for Best macular dystrophy. Nat Genet 1998; 19:241-7. [PMID: 9662395]
3. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment

3086
epithelium. Proc Natl Acad Sci USA 2000; 97:12758-63. [PMID: 11050159]

4. Hartzell HC, Qu Z, Yu K, Xiao Q, Chien LT. Molecular Physiology of Bestrophins: Multifunctional Membrane Proteins Linked to Best Disease and Other Retinopathies. Physiol Rev 2008; 88:639-72. [PMID: 18391176]

5. Xiao Q, Hartzell HC, Yu K. Bestrophins and retinopathies. Pflugers Arch 2010; 460:559-69. [PMID: 20349192]

6. Boon CJF, Klevering BJ, Leroy BP, Hoyng CB, Keunen JJE, den Hollander AI. The spectrum of oculophenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 2009; 28:187-205. [PMID: 19375515]

7. Gass JDM. Best’s Disease. in: Stereoscopic Atlas of Macular Disease. Diagnosis and Treatment. St. Louis-London-Philadelphia-Sydney-Toronto; Mosby: 1997. p. 304–313.

8. Deutman AF, Hoyng CB. Macular Dystrophies. in Ryan SJ editor. Retina. St. Louis-London-Philadelphia-Sydney-Toronto; Mosby: 2001. p. 1210–1257.

9. Spaide RF, Noble K, Morgan A, Freund KB. Vitelliform macular dystrophy. Ophthalmology 2006; 113:1392-400. [PMID: 16877078]

10. Krämer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Spaide RF, Noble K, Morgan A, Freund KB. Vitelliform macular dystrophy. Ophthalmology 2006; 113:1392-400. [PMID: 16877078]

11. Yardley J, Leroy BP, Urquhart JE, Fearon IM, De Baere E, Brown PD, Robson AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FD, Black GC. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008; 82:19-31. [PMID: 18179881]

12. Davidson AE, Millar ID, Urquhart JE, Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, De Baere E, Brown PD, Robson AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FD, Black GC. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008; 82:19-31. [PMID: 18179881]

13. Michaelides M, Urquhart J, Holder GE, Restori M, Kayali N, Manson FD, Black GC. Evidence of genetic heterogeneity in MRCS (microcornea, rod-cone dystrophy, cataract, and posterior staphyloma) syndrome. Am J Hum Genet 2009; 85:581-92. [PMID: 19853238]

14. Schatz P, Klar J, Andréasson S, Ponjivac V, Dahl N. Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet 2006; 27:51-6. [PMID: 16754206]

15. Bakall B, Radu RA, Stanton JB, Burke JM, McKay BS, Wadelius C, Mullins RF, Stone EM, Travis GH, Marmorstein AD. Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res 2007; 85:34-43. [PMID: 17477921]

16. Querques G, Zerib J, Santacroce R, Margaglione M, Delphin N, Rozet JM, Kaplan J, Martellini D, Delle Noci N, Soubra G, Souied EH. Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene. Mol Vis 2009; 15:2960-72. [PMID: 20057903]

17. Wong RL, Hou P, Choy KW, Chiang SW, Tam PO, Li H, Chan WM, Lam DS, Pang CP, Lai TY. Novel and homozygous BEST1 mutations in Chinese patients with Best vitelliform macular dystrophy. Retina 2010; 30:820-7. [PMID: 20057343]

18. Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, De Baere E, Brown PD, Robson AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FD, Black GC. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008; 82:19-31. [PMID: 18179881]

19. Kerth C, Zawadzki RJ, Werner JS, Héon E. Detailed analysis of retinal function and morphology in a patient with autosomal recessive bestrophinopathy (ARB). Doc Ophthalmol 2009; 118:239-46. [PMID: 18985398]

20. Bitner H, Mizrahi-Meissonnier L, Griefner G, Erdinest I, Sharon D, Banin E. A homozygous frameshift mutation in BEST1 causes the classical form of Best disease in an autosomal recessive mode. Invest Ophthalmol Vis Sci 2011; 52:5332-8. [PMID: 21467170]

21. Iannaccone A, Kerr NC, Kinnick TR, Calzada JI, Stone EM. Autosomal Recessive Best Vitelliform Macular Dystrophy Report of a Family and Management of Early-Onset Neovascular Complications. Arch Ophthalmol 2011; 129:211-7. [PMID: 21320969]

22. Kinnick TR, Mullins RF, Dev S, Leys M, Mackay DA, Kay CN, Lam BL, Fishman GA, Traboulsi E, Iezzi R, Stone EM. Autosomal recessive vitelliform macular dystrophy in a large cohort of vitelliform macular dystrophy patients. Retina 2011; 31:581-95. [PMID: 21273940]

23. Brown M, Marmor M, Vaegan E, Zrenner E, Brigg M, Bach M; ISCEV. ISCEV Standard for Clinical Electro-oculography (EOG) 2006. Doc Ophthalmol 2006; 113:205-12. [PMID: 17109157]

24. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigg M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electoretinography (2008 update). Doc Ophthalmol 2009; 118:69-77. [PMID: 19030905]

25. Lotery AJ, Munier FL, Fishman GA, Weleber RG, Jacobson SG, Affatigato LM, Nichols BE, Schorderet DF, Sheffield VC, Stone EM. Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci 2000; 41:1291-6. [PMID: 10798642]

26. Maia-Lopes S, Castelo-Branco M, Silva E, Aguirre J, Riveiro-Alvarez R, Trujillo-Tiebas MJ, Ayuso C. Gene symbol: BEST1. Disease: Best macular dystrophy. Hum Genet 2008; 123:112. [PMID: 18386373]